Danish pharmaceutical company Novo Nordisk fell 21% on the Copenhagen stock exchange after announcing the main results of the Redefine-1 study, according to a press release.
The stock is headed for its worst trading day since April 2002.
“Evaluating the treatment effects if all subjects completed treatment1, subjects treated with Cagrisema achieved a 22.7 percent greater weight loss after 68 weeks, compared to an 11.8 percent reduction with cagrilintide 2, 4 mg, by 16.1 percent with semaglutide 2.4 mg, and by 2.3 percent with placebo alone. Additionally, 40.4 percent of patients taking Cagrisema had achieved weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with placebo.
Redefine-1 is a Phase 3 study analyzing Subcutaneous Cagrisema compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once weekly.
“The study included 3,417 randomized obese or overweight people with one or more comorbidities and an average baseline body weight of 106.9 kg. The study met its primary endpoint by demonstrating statistically significant and greater weight loss at week 68 with Cagrisema compared to placebo,” writes Novo.
